New drug duo targets deadly brain cancer in early trial
NCT ID NCT07392957
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental drugs, CTX-009 and CTX-471, in people whose glioblastoma has returned after standard treatment. The goal is to see if these drugs are safe and can help control the tumor or extend survival. About 54 participants will receive either CTX-009 alone or together with CTX-471.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Brain cancer vaccine targets survivin protein to boost immune attack
- Targeted antibody may boost brain cancer treatment after incomplete surgery
- Spinal fluid DNA test could personalize brain cancer therapy
- Tailored radiation blasts brain tumors where They're most likely to return
- Personalized vaccine takes aim at recurrent brain tumors